Drugs / m170
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00009763 | Mar 2001 → ? | breast cancer | University of California, Davis | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00009750 Background | Mar 2001 → ? | prostate cancer | University of California, Davis | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | m170 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00009750 ↗ |
| Known as | MOAB m170 | “Patients receive unlabeled monoclonal antibody (MOAB) m170 IV followed by a tracer dose of indium In 111 MOAB m170 IV on day 0.” NCT00009763 ↗ |
| Modality | Monoclonal antibody | “unlabeled monoclonal antibody (MOAB) m170” NCT00009750 ↗ |
| Route | Intravenous | “unlabeled MOAB m170 IV” NCT00009750 ↗ |
| Target | MUC1 | “Mucin-1 binding agent” CHEMBL2109523 ↗ |